Coherus Oncology, Inc.
NASDAQ:CHRSBiotechnology
+$0.03 today
- Market cap
- $63.35M
- Beta
- 0.96
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$1.11
Volume 2.55M
Average 1.15M
CHRS EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Coherus Oncology, Inc.NASDAQ: CHRS
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$33.87M, compared with -$44.2M a year earlier. Trailing-twelve-month EBITDA was -$159.87M.
Context
- EBITDA amounted to 403.6% of revenue in FY2025, up 380.8 pp from a year earlier.
- EBITDA increased in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 5 analysts of -$72.45M (+57.4%) for the fiscal year ending Dec 2026, a step up from the -379.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$33.87M+21.6% QoQ
- Last fiscal yearDec 2025
- -$170.2M-379.3% YoY
- LTMMar 2026
- -$159.87M-61.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +23.4% | +14.5% | -8.9 pp |
| 1 year | -379.3% | +57.4% | +436.7 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (170.2M) USD
- Year-over-year change
- -379.3%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (170.2M) | -379.3% |
| FY2024 | 2024-12-31 | 60.94M | +131.4% |
| FY2023 | 2023-12-31 | (193.94M) | +24.1% |
| FY2022 | 2022-12-31 | (255.58M) | +2.0% |
| FY2021 | 2021-12-31 | (260.69M) | — |
EBITDA vs competitors
How CHRS compares with its peers on the latest reported figures
- CHRS's LTM Mar 2026 EBITDA of -$159.87M is the lowest of the 11 companies compared; the peer median is -$54.17M.
- Its year-over-year change of -61.9% is the 8th highest of 11, against a peer median of +7.9%.
- EBITDA amounts to 341.0% of revenue for CHRS, versus a peer median of 211.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $22.33M | +211.8% | — | 29.2% | |
| LTM Mar 2026 | -$22.06M | +62.9% | — | 28.2% | |
| LTM Mar 2026 | -$33.82M | +24.4% | — | 117.0% | |
| LTM Sep 2026 | -$35.76M | -89.6% | — | — | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | -$45.4M | +19.5% | — | 2329.5% |
| LTM Mar 2026 | -$62.94M | -39.6% | — | — | |
| LTM Mar 2026 | -$75.72M | +45.7% | — | 135.5% | |
| LTM Mar 2026 | -$84.35M | -214.9% | — | 142957.6% | |
| LTM Mar 2026 | -$100.38M | -3.7% | — | 287.9% | |
| LTM Mar 2026 | -$117.46M | -66.2% | — | 339.9% | |
| LTM Mar 2026 | -$159.87M | -61.9% | — | 341.0% | |
| Peer median (excluding CHRS) | -$54.17M | +7.9% | — | 211.7% | |
Competitors are the stored peer set for CHRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 326.55M | 211.04M | 257.24M | 266.96M | 42.17M |
| Cost of Revenue | 57.59M | 70.08M | 158.99M | 117.55M | 17.74M |
| Gross Profit | 268.96M | 140.96M | 98.25M | 149.41M | 24.43M |
| Gross Margin | 82.4% | 66.8% | 38.2% | 56.0% | 57.9% |
| Research & Development | 363.11M | 199.36M | 109.44M | 93.34M | 104.96M |
| Selling, General & Admin | 169.71M | 198.48M | 185.62M | 150.44M | 99M |
| Operating Expenses | 532.82M | 397.84M | 301.45M | 261.07M | 203.97M |
| Depreciation & Amortization | 3.45M | 3.7M | 3.79M | 5.28M | 3.92M |
| EBITDA | (260.69M) | (255.58M) | (193.94M) | 60.94M | (170.2M) |
| EBITDA Margin | -79.8% | -121.1% | -75.4% | 22.8% | -403.6% |
| Operating Income | (263.86M) | (256.88M) | (203.2M) | (111.67M) | (179.53M) |
| Operating Margin | -80.8% | -121.7% | -79.0% | -41.8% | -425.7% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 22.96M | 32.47M | 40.54M | 27.16M | 9M |
| Other Income / Expenses | (23.24M) | (34.87M) | (35.07M) | 140.17M | (3.59M) |
| Income Before Tax | (287.1M) | (291.75M) | (238.27M) | 28.51M | (183.12M) |
| Pre-Tax Margin | -87.9% | -138.2% | -92.6% | 10.7% | -434.2% |
| Income Tax Expense | 0 | 0 | (380K) | 0 | 0 |
| Net Income | (287.1M) | (291.75M) | (237.89M) | 28.51M | (170.29M) |
| Net Margin | -87.9% | -138.2% | -92.5% | 10.7% | -403.8% |
| EPS (Basic) | (3.81) | (3.76) | (2.53) | 0.25 | (1.45) |
| EPS (Diluted) | (3.81) | (3.76) | (2.53) | 0.25 | (1.45) |
| Weighted Avg Shares | 75.45M | 77.63M | 94.16M | 114.55M | 120.37M |
| Weighted Avg Shares (Diluted) | 75.45M | 77.63M | 94.16M | 114.83M | 120.37M |
Coherus Oncology, Inc.
NASDAQ:CHRS
Intrinsic Alpha fair value
Locked
Current Price
$0.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.